Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | PFKFB4 | Q16877 | 4/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 2/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3483800 | 0.98 | CA12 (0.38) | CA12CA1CA2CA9PFKFB4 | |
| SCHEMBL3484384 | 0.93 | PFKFB4 (0.38) | PFKFB4PFKFB3CMA1PLA2G2A | |
| Trifluoroacetic Acid SCHEMBL4199110 | 0.87 | CACNA1B (0.34) | CA12CA1CA2CA9CACNA1B | |
| Trifluoroacetic Acid SCHEMBL14931254 | 0.86 | CACNA1B (0.35) | CA12CA1CA2CA9CACNA1B | |
| Trifluoroacetic Acid SCHEMBL3483985 | 0.83 | CA2 (0.39) | CA12CA1CA2CA9CACNA1B | |
| Trifluoroacetic Acid SCHEMBL3483752 | 0.82 | CA2 (0.39) | CA12CA1CA2CA9CACNA1B | |
| SCHEMBL4204282 | 0.80 | TRPV4 (0.36) | PFKFB4PFKFB3 | |
| SCHEMBL3483847 | 0.80 | CMA1 (0.41) | PFKFB4PFKFB3CMA1 | |
| SCHEMBL3483432 | 0.79 | CMA1 (0.34) | PFKFB4PFKFB3CMA1PLA2G2A | |
| SCHEMBL13032311 | 0.79 | TRPV4 (0.35) | PFKFB4PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CA12 3327/4885CA1 3102/4885CA2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.